Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 6Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

Neurofibromatoses 1NF1 1Melanoma 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × mirdametinib × Dermatologic × Clear all
NCT06159166 2026-04-13

Mirda

Johns Hopkins University

Phase 1/2 Recruiting
24 enrolled
CNSDermatologic

NF1

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Sutter Health

Phase 2 Recruiting
10 enrolled
CNSDermatologic

Melanoma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡